Zhejiang Huahai Pharmaceutical Co Ltd, based in China, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
One of their notable products is VORTIOXETINE HYDROBROMIDE, with a corresponding US DMF Number 40535.
Remarkably, this DMF maintains an Active status since its submission on September 26, 2024, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of December 12, 2024, and payment made on November 04, 2024, indicating their dedication to facilitating drug approvals, Categorized as Type II